Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. [electronic resource]
Producer: 20190305Description: 1573-1579 p. digitalISSN:- 1521-4141
- Autoantibodies -- blood
- Bortezomib -- therapeutic use
- Complement System Proteins -- metabolism
- Humans
- Immunoglobulins -- blood
- Lupus Erythematosus, Systemic -- drug therapy
- Lymphocyte Count
- Plasma Cells -- cytology
- Precursor Cells, B-Lymphoid -- cytology
- Precursor Cells, T-Lymphoid -- cytology
- Proteasome Endopeptidase Complex -- drug effects
- Proteasome Inhibitors -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.